Bio-Techne Aktie
WKN DE: A12ENG / ISIN: US09073M1045
19.12.2024 13:44:56
|
Bio-Techne, Waters Announce Biotherapeutic Characterization Co-marketing Agreemenent
(RTTNews) - Bio-Techne Corporation (TECH), a provider of life science reagents, instruments and services, Thursday announced a co-marketing and co-promotion agreement with Waters Corporation to expand biotherapeutic characterization and development processes.
The companies plan to combine Bio-Techne's MauriceFlex System for charge separation and BioAccord LC-MS System for liquid chromatography mass spectrometry from Waters to provide new solutions that optimize workflows, improve accuracy, and expedite development timelines.
The companies have already started many activities together and Scientists and commercial team members from both companies have participated in a number of projects, including the publication of an application note, a webinar, poster presentations, and talks at major conferences including CASSS MS, Festival of Biologics and PEGS EU.
Application scientists from both companies are planning to announce joint results from the analysis of additional classes of biomolecules at the upcoming scientific conferences. The company noted that this work will guide application notes, webinars, and presentations at upcoming Bio-Techne User Group Meetings to co-market each company's advanced biotherapeutic characterization and development process capabilities.
"Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster," said Will Geist, President of the Protein Sciences Segment at Bio-Techne.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
25.09.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust hätte eine Bio-Techne-Investition von vor einem Jahr eingebracht (finanzen.at) | |
18.09.25 |
S&P 500-Wert Bio-Techne-Aktie: So viel Gewinn hätte eine Investition in Bio-Techne von vor 10 Jahren abgeworfen (finanzen.at) | |
12.09.25 |
Handel in New York: S&P 500 nachmittags mit grünem Vorzeichen (finanzen.at) | |
12.09.25 |
Zurückhaltung in New York: S&P 500 fällt am Mittag zurück (finanzen.at) | |
11.09.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust hätte eine Bio-Techne-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
10.09.25 |
S&P 500-Handel aktuell: Börsianer lassen S&P 500 letztendlich steigen (finanzen.at) | |
10.09.25 |
Börse New York: S&P 500 legt nachmittags zu (finanzen.at) | |
04.09.25 |
S&P 500-Wert Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor 3 Jahren verloren (finanzen.at) |
Analysen zu Bio-Techne Corpmehr Analysen
Aktien in diesem Artikel
Bio-Techne Corp | 43,00 | -0,46% |
|